15-min delayed · Aug 26, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Kiora Pharmaceuticals Inc, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $10.00 to $10.00, so the covering firms are broadly aligned. The average target of $10.00 sits 286% above the current $2.59. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.42 next quarter toward $-1.41 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Strong Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Kiora Pharmaceuticals Inc.
As of Aug, 1 of 1 firms rate KPRX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
KPRX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.42
Range $-0.42 – $-0.42 · 1 analysts · -73% YoY
Next period, 1 analysts expect Kiora Pharmaceuticals Inc to earn $-0.42 a share (range $-0.42 – $-0.42), versus $-1.56 a year earlier. Full-year consensus is $-1.67, growing to $-1.41 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Kiora Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on KPRX.
#1
Yi Chen
HC Wainwright & Co. · Rank #276
Buy
$10.00+286.1% to target
Overall win rate
33%
+ Follow
KPRX stock forecast FAQ
What is KPRX's average 12-month price target?+
The 1 analysts with a live target average $10.00 for Kiora Pharmaceuticals Inc over the next 12 months, ranging from a $10.00 high to a $10.00 low.
Is KPRX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover KPRX?+
1 analysts have an active rating on Kiora Pharmaceuticals Inc, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering KPRX?+
Among analysts who currently cover KPRX, Yi Chen of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #276). Their current call is Buy with a $10.00 target.
What is Kiora Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.42 per share (range $-0.42 – $-0.42) across 1 analysts. Full-year EPS is projected at $-1.67, rising to $-1.41 the following year.
How much revenue is Kiora Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading KPRX lately?+
As of Aug, 1 of 1 firms rate KPRX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their KPRX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
